bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events

Item 8.01 Other Events

On June 26, 2017, bluebird bio, Inc. reported updated clinical
data from the Starbeam Study clinical study of its Lenti-D
product candidate. The full text of bluebird bio, Inc.s press
release regarding the announcement is filed as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by
reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_37.htm EX-99.1 blue-ex991_37.htm     Exhibit 99.1   bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy (CALD)     – 15/17 patients (88%) in initial study cohort remain free of major functional disabilities (MFDs) at 24 months –   – Expansion cohort enrolling additional patients to gain European manufacturing experience –   CAMBRIDGE,…
To view the full exhibit click here
About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.